Numeco Secures Product Approval for Botulinum Toxin 'Newlux' in Panama
Entry into Five Central and South American Countries
Numeco, a subsidiary of Medytox, announced on August 20 that it has obtained product approval for the botulinum toxin formulation 'Newlux' from Panama’s Drug and Food Administration (DNFD).
With this approval, Numeco has now expanded into five countries in Central and South America, including Peru, Bolivia, the Dominican Republic, and El Salvador.
Numeco plans to continue its partnership with the local distributor that has been leading sales of Medytox's botulinum toxin formulation Meditoxin (exported under the name Neuronox) in the region for over ten years.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Numeco representative stated, "Central and South America is a market with significant growth in K-aesthetics. By leveraging the global business capabilities and networks that Medytox has accumulated, we will further strengthen the brand presence of the botulinum toxin formulation 'Newlux.'"
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.